NASDAQ:BLPHBellerophon Therapeutics Stock Price, Forecast & News

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BLPH shares have increased by 106.4% and is now trading at $12.98. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bellerophon Therapeutics.

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Bellerophon Therapeutics.

Bellerophon Therapeutics Inc (NASDAQ:BLPH) posted its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.13. View Bellerophon Therapeutics' earnings history.

Bellerophon Therapeutics's stock reverse split on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

3 equities research analysts have issued 12-month price targets for Bellerophon Therapeutics' shares. Their forecasts range from $30.00 to $35.00. On average, they expect Bellerophon Therapeutics' share price to reach $31.67 in the next twelve months. This suggests a possible upside of 144.0% from the stock's current price. View analysts' price targets for Bellerophon Therapeutics.

News coverage about BLPH stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bellerophon Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View the latest news about Bellerophon Therapeutics.

Bellerophon Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 380,700 shares, an increase of 245.5% from the June 15th total of 110,200 shares. Based on an average daily volume of 451,600 shares, the days-to-cover ratio is currently 0.8 days. Currently, 7.1% of the shares of the stock are sold short. View Bellerophon Therapeutics' Current Options Chain.

Some companies that are related to Bellerophon Therapeutics include Viking Therapeutics (VKTX), AC Immune (ACIU), Mirum Pharmaceuticals (MIRM), BioSpecifics Technologies (BSTC), Satsuma Pharmaceuticals (STSA), Beyondspring (BYSI), Flexion Therapeutics (FLXN), Emisphere Technologies (EMIS), Xenon Pharmaceuticals (XENE), Merus (MRUS), Zafgen (ZFGN), Geron (GERN), TherapeuticsMD (TXMD), Prothena (PRTA) and DURECT (DRRX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Vaxart (VXRT), Novavax (NVAX), VBI Vaccines (VBIV), Opko Health (OPK), Verastem (VSTM), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Clovis Oncology (CLVS).

(BLPH) raised $60 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BLPH stock can currently be purchased for approximately $12.98.

Bellerophon Therapeutics has a market capitalization of $123.28 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe.

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]